Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoDoce Intratumoral Injection in Localized Renal Cell Carcinoma
NCT04260360Phase 1Withdrawn
- Sponsor
- NanOlogy
- Start
- Apr 2020
- Primary completion
- Jun 2022
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of NanoDoce in renal cell carcinoma (RCC), sponsored by NanOlogy. Primary endpoint: Number of participants with treatment emergent adverse events. Planned start Apr 2020; status: withdrawn.
02
Drugs
NanoDoce
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04260360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260360.